



Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective 2/06/2020, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than the Generic Program:

- Nuvaring and Symbicort inhaler will be ADDED to the program. Voltaren Gel and Zytiga will be REMOVED from the program.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription. Have a generic copayment. Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied). Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION

Prescription claims submitted to the Medicaid program do not require the submission of Dispense as Written/Product Selection Code of '1'; Pharmacies can submit any valid NCPDP field (408-D8) value.

List of Brand Name Drugs included in this program\* (updated 01/06/2020)

Table with 3 columns listing brand name drugs such as Aggrenox, Fosrenol, Retin-A, Alphagan P, Humalog, Sensipar, Androgel, Letairis, Suboxone, Butrans, Lexiva, Symbicort, Catapres-TTS, Mitigare, Tegretol, Cellcept, Nuvaring, Tracleer, Copaxone, Norvir, Transderm-Scop, Diclegis, ProAir, Xeloda, Elidel, Protopic, Zovirax, Exelon, Rapamune, and Focalin, Renagel.

\*List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.